Literature DB >> 27186290

Galectin-1 mediates TGF-β-induced transformation from normal fibroblasts into carcinoma-associated fibroblasts and promotes tumor progression in gastric cancer.

Lingyan Zheng1, Cong Xu1, Zhonghai Guan1, Xingyun Su1, Zhenzhen Xu1, Jiang Cao2, Lisong Teng1.   

Abstract

Rcinoma-associated fibroblasts (CAFs) are a major constituent of the tumor microenvironment. Cancer cells can induce the transformation from normal fibroblasts (NFs) into CAFs, reciprocally, CAFs promote tumor invasion and proliferation. TGF-β has been the mostly accepted factor to fuel NFs transformation into CAFs. Galectin-1 (Gal1) is highly upregulated in CAFs of multiple human cancers, and overexpression of Gal1 in CAFs promotes tumor progression. The effect of Gal1 on TGF-β-induced CAFs activation has not yet been established in gastric cancer (GC). In this study, we show that Gal1 expression in stroma is positively related to TGF-β in epithelial cells by retrospective analysis of GC patient samples. Meanwhile, conditioned media (CMs) from gastric cancer cells induce expression of both Gal1 and the CAFs marker alpha smooth muscle actin (α-SMA) in NFs via TGF-β secretion. Knockdown of Gal1 prevents TGF-β-induced the conversion of NFs to CAFs. CMs from fibroblasts overexpressing Gal1 inhibits cancer cells apoptosis, promotes migration and invasion in vitro. Thus, Gal1 is significantly involved in the development of tumor-promoting microenvironment by enhancing TGF-β signaling in a positive feedback loop. Targeting Gal1 in tumor stroma should be considered as a potential therapeutic target for GC.

Entities:  

Keywords:  Stric cancer; TGF-β; carcinoma-associated fibroblast; galectin-1; normal fibroblast; transformation

Year:  2016        PMID: 27186290      PMCID: PMC4859895     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  54 in total

Review 1.  Mechanisms of TGF-beta signaling from cell membrane to the nucleus.

Authors:  Yigong Shi; Joan Massagué
Journal:  Cell       Date:  2003-06-13       Impact factor: 41.582

2.  Galectin-1 inhibits the viability, proliferation, and Th1 cytokine production of nonmalignant T cells in patients with leukemic cutaneous T-cell lymphoma.

Authors:  Filiberto Cedeno-Laurent; Rei Watanabe; Jessica E Teague; Thomas S Kupper; Rachael A Clark; Charles J Dimitroff
Journal:  Blood       Date:  2012-03-01       Impact factor: 22.113

3.  Galectin-1 is silenced by promoter hypermethylation and its re-expression induces apoptosis in human colorectal cancer cells.

Authors:  Arun Satelli; U Subrahmanyeswara Rao
Journal:  Cancer Lett       Date:  2010-11-30       Impact factor: 8.679

4.  Adhesion/growth-regulatory tissue lectin galectin-1 in relation to angiogenesis/lymphocyte infiltration and prognostic relevance of stromal up-regulation in laryngeal carcinomas.

Authors:  Sven Saussez; Christine Decaestecker; Stéphanie Cludts; Perle Ernoux; Dominique Chevalier; Karel Smetana; Sabine André; Xavier Leroy; Hans-Joachim Gabius
Journal:  Anticancer Res       Date:  2009-01       Impact factor: 2.480

5.  Oxidative stress promotes myofibroblast differentiation and tumour spreading.

Authors:  Aurore Toullec; Damien Gerald; Gilles Despouy; Brigitte Bourachot; Melissa Cardon; Sylvain Lefort; Marion Richardson; Guillem Rigaill; Maria-Carla Parrini; Carlo Lucchesi; Dorine Bellanger; Marc-Henri Stern; Thierry Dubois; Xavier Sastre-Garau; Olivier Delattre; Anne Vincent-Salomon; Fatima Mechta-Grigoriou
Journal:  EMBO Mol Med       Date:  2010-06       Impact factor: 12.137

6.  VEGFR1 and VEGFR2 involvement in extracellular galectin-1- and galectin-3-induced angiogenesis.

Authors:  Nicky D'Haene; Sébastien Sauvage; Calliope Maris; Ivan Adanja; Marie Le Mercier; Christine Decaestecker; Linda Baum; Isabelle Salmon
Journal:  PLoS One       Date:  2013-06-17       Impact factor: 3.240

7.  Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi's sarcoma.

Authors:  Diego O Croci; Mariana Salatino; Natalia Rubinstein; Juan P Cerliani; Lucas E Cavallin; Howard J Leung; Jing Ouyang; Juan M Ilarregui; Marta A Toscano; Carolina I Domaica; María C Croci; Margaret A Shipp; Enrique A Mesri; Adriana Albini; Gabriel A Rabinovich
Journal:  J Exp Med       Date:  2012-10-01       Impact factor: 14.307

8.  Galectin-1 is overexpressed in CD133+ human lung adenocarcinoma cells and promotes their growth and invasiveness.

Authors:  Xuefeng Zhou; Dan Li; Xianguo Wang; Bo Zhang; Hua Zhu; Jinping Zhao
Journal:  Oncotarget       Date:  2015-02-20

9.  Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer.

Authors:  P Zhang; P Zhang; B Shi; M Zhou; H Jiang; H Zhang; X Pan; H Gao; H Sun; Z Li
Journal:  Cell Death Dis       Date:  2014-01-09       Impact factor: 8.469

10.  Galectin-1-mediated cell adhesion, invasion and cell death in human anaplastic large cell lymphoma: regulatory roles of cell surface glycans.

Authors:  Osamu Suzuki; Masafumi Abe
Journal:  Int J Oncol       Date:  2014-03-04       Impact factor: 5.650

View more
  7 in total

Review 1.  Contribution of galectin-1, a glycan-binding protein, to gastrointestinal tumor progression.

Authors:  María L Bacigalupo; Pablo Carabias; María F Troncoso
Journal:  World J Gastroenterol       Date:  2017-08-07       Impact factor: 5.742

2.  Galectin-1 knockdown improves drug sensitivity of breast cancer by reducing P-glycoprotein expression through inhibiting the Raf-1/AP-1 signaling pathway.

Authors:  Fang Wang; Pengwei Lv; Yuanting Gu; Lin Li; Xin Ge; Guangcheng Guo
Journal:  Oncotarget       Date:  2017-04-11

Review 3.  Galectins as Molecular Targets for Therapeutic Intervention.

Authors:  Ruud P M Dings; Michelle C Miller; Robert J Griffin; Kevin H Mayo
Journal:  Int J Mol Sci       Date:  2018-03-19       Impact factor: 5.923

4.  BP‑1‑102 exerts an antitumor effect on the AGS human gastric cancer cell line through modulating the STAT3 and MAPK signaling pathways.

Authors:  Xiaoxia Jiang; Jian Tang; Mengjie Wu; Shitu Chen; Zhenzhen Xu; Haiyong Wang; Haohao Wang; Xiongfei Yu; Zhongqi Li; Lisong Teng
Journal:  Mol Med Rep       Date:  2019-01-24       Impact factor: 2.952

5.  Galectin-1 Promotes Vasculogenic Mimicry in Gastric Cancer by Upregulating EMT Signaling.

Authors:  Xiaolan You; Qinghong Liu; Jian Wu; Yuanjie Wang; Jiawen Dai; Dehu Chen; Yan Zhou; Yanjun Lian
Journal:  J Cancer       Date:  2019-10-17       Impact factor: 4.207

6.  Galectin-1 promotes hepatocellular carcinoma and the combined therapeutic effect of OTX008 galectin-1 inhibitor and sorafenib in tumor cells.

Authors:  Zoe Leung; Frankie Chi Fat Ko; Sze Keong Tey; Ernest Man Lok Kwong; Xiaowen Mao; Bonnie Hei Man Liu; Angel Po Yee Ma; Yi Man Eva Fung; Chi-Ming Che; Danny Ka Ho Wong; Ching Lung Lai; Irene Oi-Lin Ng; Judy Wai Ping Yam
Journal:  J Exp Clin Cancer Res       Date:  2019-10-22

7.  Galectin-1 prevents pathological vascular remodeling in atherosclerosis and abdominal aortic aneurysm.

Authors:  Raquel Roldán-Montero; Juan M Pérez-Sáez; Isabel Cerro-Pardo; Jorge Oller; Diego Martinez-Lopez; Estefania Nuñez; Sebastian M Maller; Carmen Gutierrez-Muñoz; Nerea Mendez-Barbero; Joan C Escola-Gil; Jean-Baptiste Michel; Maria Mittelbrunn; Jesús Vázquez; Luis M Blanco-Colio; Gabriel A Rabinovich; Jose L Martin-Ventura
Journal:  Sci Adv       Date:  2022-03-16       Impact factor: 14.136

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.